Evidence map›Paper›PMID 26208812›Full record

ReviewCurrent HIV/AIDS reports2015

Extrahepatic manifestations of hepatitis C infection: navigating CHASM.

Amy C Sherman, Kenneth E Sherman

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current HIV/AIDS reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Treatment of Hepatitis C Virus and Long-Term Effect on Glycemic Control.Journal of managed care & specialty pharmacy · 2020
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Global epidemiology and burden of HCV infection and HCV-related disease.Nature reviews. Gastroenterology & hepatology · 2017
    Review
  16. Systemic manifestations of hepatitis C infection.Infectious agents and cancer · 2016
    Review
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Amy C ShermanEmory University School of Medicine, Atlanta, GA, USA.
Kenneth E Sherman

Funding

Mentorship in Liver DiseaseK24DK070528 · NIDDK · UNIVERSITY OF CINCINNATI · PI SHERMAN, KENNETH E · 2005 to 2014
$1.4M
NIDDK NIH HHS K24 DK070528PHS HHS K24 070528
6 · The paper itself

Abstract

This article describes the importance of extrahepatic systemic manifestations of chronic hepatitis C virus (HCV) infection. While most HCV literature focuses on liver injury and fibrosis progression, a spectrum of systemic disease processes, collectively called C hepatitis-associated systemic manifestations (CHASMs), are present in a high proportion of infected persons. These include thyroid disease (Hashimoto's thyroiditis, Graves disease, and thyroid cancer), cardiovascular disease (atherosclerosis, carotid artery disease, and coronary artery disease), renal disease (MPGN and glomerulosclerosis), eye disease (Mooren's ulcers and sicca syndrome), skin disease (PCT, vasculitis, and lichen planus), lymphomas (NHL and splenic T-cell), and diabetes. Mechanistic understanding of how HCV leads to CHASM processes could lead to development of new interventions. The role of early HCV treatment and cure may result in preventive strategies for a variety of complex disease states. Key Points • Systemic extrahepatic complications of HCV comprise a spectrum of disease states in many organs and systems.• Effective treatment of HCV may reduce or eliminate some but not all of these systemic complications.• Further research into early treatment intervention as a prevention strategy for systemic disease is warranted.

Indexed as

Autoimmune DiseasesHematologic DiseasesHepatitis C, ChronicHumansKidney DiseasesLymphomaMetabolic DiseasesSjogren's SyndromeSkin Diseases

Identifiers

PMID26208812
PMCPMC4554601

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.